MRI Interventions’ ClearPoint® Neuro Navigation System Reaches Milestone With Its 1,000th Procedure

IRVINE, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint Neuro Navigation System was utilized for its 1,000th neurosurgical procedure.  

“More than one thousand patients have now benefited from the sub-millimeter accuracy and real-time, MRI-based visualization enabled by our ClearPoint Neuro Navigation System during brain surgeries such as electrode insertion, biopsies and catheter placement,” commented Frank Grillo, President and CEO of MRI Interventions.  “As adoption of our technology continues to grow, we are proud to work with innovative neurosurgeons and medical centers to offer minimally invasive surgical options for their patients.”

The ClearPoint system allows surgeons to plan, target, and adjust trajectories under continuous real-time MRI-guided visualization.  Since receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2010, the ClearPoint system has been utilized by more than 40 leading institutions across the country. 

"The ClearPoint System combines highly accurate stereotactic targeting with intra-operative MRI confirmation and improved patient comfort and safety," said Dr. Rees Cosgrove, Director of Epilepsy and Functional Neurosurgery at Brigham and Women’s Hospital, Boston, who performed the one-thousandth procedure.

About MRI Interventions, Inc.

Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures.  The ClearPoint System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements.  Particular uncertainties and risks include those relating to: customer demand and market acceptance of the Company’s products; its ability to successfully expand, and achieve full productivity from, its sales, clinical support and marketing capabilities; its ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of its cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact its commercialization efforts.  More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Form 10-K for the year ended December 31, 2014, as well as the Company’s Form 10-Q for the quarter ended September 30, 2015, which have been filed with the Securities and Exchange Commission.



Contact Data